Details of the Drug

General Information of Drug (ID: DM1MBYQ)

Drug Name
Ganciclovir
Synonyms
ganciclovir; 82410-32-0; Gancyclovir; Cytovene; Vitrasert; Hydroxyacyclovir; Ganciclovirum; Zirgan; RS-21592; Cymevene; HHEMG; Biolf 62; BW-759U; Ganciclovirum [Latin]; 2'-NDG; 2-Amino-9-(((1,3-dihydroxypropan-2-yl)oxy)methyl)-1H-purin-6(9H)-one; BW 759U; BIOLF-62; 2'-Nor-2'-deoxyguanosine; 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine; BW-B 759U; UNII-P9G3CKZ4P5; DRG-0018; BW 759; 9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one; CCRIS 9212; GA2; Cytovene-IV; HSDB 6512
Indication
Disease Entry ICD 11 Status REF
Virus infection 1A24-1D9Z Approved [1]
Therapeutic Class
Antiviral Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 255.23
Topological Polar Surface Area (xlogp) -2.5
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [2]
Clearance
The drug present in the plasma can be removed from the body at the rate of 4.6 mL/min/kg [3]
Elimination
91% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 2.5 - 3.6 hours [3]
Metabolism
The drug is not metabolised [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 78.3591 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.99% [3]
Vd
The volume of distribution (Vd) of drug is 0.74 +/- 0.15 L/kg [6]
Water Solubility
The ability of drug to dissolve in water is measured as 6 mg/mL [2]
Chemical Identifiers
Formula
C9H13N5O4
IUPAC Name
2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-1H-purin-6-one
Canonical SMILES
C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N
InChI
InChI=1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17)
InChIKey
IRSCQMHQWWYFCW-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
135398740
ChEBI ID
CHEBI:465284
CAS Number
82410-32-0
DrugBank ID
DB01004
TTD ID
D05ARP
VARIDT ID
DR00027
ACDINA ID
D00298

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Herpes simplex virus DNA polymerase UL30 (HSV UL30) TTIU7X1 DPOL_HHV11 Inhibitor [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Alanine/serine/cysteine/threonine transporter 2 (SLC1A5) DTW7AE3 AAAT_HUMAN Substrate [8]
Multidrug resistance-associated protein 5 (ABCC5) DTYVM24 MRP5_HUMAN Substrate [9]
Multidrug resistance-associated protein 4 (ABCC4) DTCSGPB MRP4_HUMAN Substrate [10]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [11]
Multidrug and toxin extrusion protein 2 (SLC47A2) DT3TX4H S47A2_HUMAN Substrate [12]
Multidrug and toxin extrusion protein 1 (SLC47A1) DTZGT0P S47A1_HUMAN Substrate [12]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [13]
Organic anion transporter 1 (SLC22A6) DTQ23VB S22A6_HUMAN Substrate [11]
Organic anion transporter 3 (SLC22A8) DTVP67E S22A8_HUMAN Substrate [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Ganciclovir (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Decreased renal excretion of Ganciclovir caused by Remdesivir mediated nephrotoxicity. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [85]
Midostaurin DMI6E0R Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Midostaurin. Acute myeloid leukaemia [2A60] [85]
Idarubicin DMM0XGL Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Idarubicin. Acute myeloid leukaemia [2A60] [85]
Inotersen DMJ93CT Major Increased risk of nephrotoxicity by the combination of Ganciclovir and Inotersen. Amyloidosis [5D00] [86]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Ganciclovir and Roflumilast. Asthma [CA23] [86]
Imipenem DMI9FBP Moderate Increased risk of lowers seizure threshold by the combination of Ganciclovir and Imipenem. Bacterial infection [1A00-1C4Z] [87]
Lomustine DMMWSUL Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Lomustine. Brain cancer [2A00] [85]
Eribulin DM1DX4Q Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Eribulin. Breast cancer [2C60-2C6Y] [85]
Talazoparib DM1KS78 Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Talazoparib. Breast cancer [2C60-2C6Y] [85]
Ixabepilone DM2OZ3G Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Ixabepilone. Breast cancer [2C60-2C6Y] [85]
LY2835219 DM93VBZ Moderate Additive myelosuppressive effects by the combination of Ganciclovir and LY2835219. Breast cancer [2C60-2C6Y] [85]
Pralatrexate DMAO80I Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Pralatrexate. Breast cancer [2C60-2C6Y] [85]
Palbociclib DMD7L94 Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Palbociclib. Breast cancer [2C60-2C6Y] [85]
Thiotepa DMIZKOP Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Thiotepa. Breast cancer [2C60-2C6Y] [85]
Cabazitaxel DMPAZHC Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Cabazitaxel. Breast cancer [2C60-2C6Y] [85]
Bosutinib DMTI8YE Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Bosutinib. Breast cancer [2C60-2C6Y] [85]
Aflibercept DMT3D5I Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Aflibercept. Colorectal cancer [2B91] [85]
Capecitabine DMTS85L Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Capecitabine. Colorectal cancer [2B91] [85]
Polatuzumab vedotin DMF6Y0L Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Polatuzumab vedotin. Diffuse large B-cell lymphoma [2A81] [85]
Lisocabtagene maraleucel DMP45ME Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Lisocabtagene maraleucel. Diffuse large B-cell lymphoma [2A81] [85]
Axicabtagene ciloleucel DMYHN59 Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Axicabtagene ciloleucel. Diffuse large B-cell lymphoma [2A81] [85]
Flucytosine DM13VTW Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Flucytosine. Endocarditis [BB40-BA42] [85]
Bay 80-6946 DMLOS5R Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Bay 80-6946. Follicular lymphoma [2A80] [85]
Avapritinib DMK2GZX Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Avapritinib. Gastrointestinal stromal tumour [2B5B] [85]
Colchicine DM2POTE Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Colchicine. Gout [FA25] [85]
177Lu-DOTATATE DMT8GVU Moderate Additive myelosuppressive effects by the combination of Ganciclovir and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [85]
Procarbazine DMIK367 Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Procarbazine. Hodgkin lymphoma [2B30] [85]
Brentuximab vedotin DMWLC57 Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Brentuximab vedotin. Hodgkin lymphoma [2B30] [85]
Teriflunomide DMQ2FKJ Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Teriflunomide. Hyper-lipoproteinaemia [5C80] [85]
Nelarabine DMB6VEG Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Nelarabine. Leukaemia [2A60-2B33] [85]
Lurbinectedin DMEFRTZ Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Lurbinectedin. Lung cancer [2C25] [85]
Osimertinib DMRJLAT Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Osimertinib. Lung cancer [2C25] [85]
Primaquine DMWQ16I Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Primaquine. Malaria [1F40-1F45] [85]
Inotuzumab ozogamicin DMAC130 Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [85]
Fludarabine DMVRLT7 Moderate Increased risk of nephrotoxicity by the combination of Ganciclovir and Fludarabine. Malignant haematopoietic neoplasm [2B33] [85]
Ofatumumab DM295PR Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Ofatumumab. Mature B-cell leukaemia [2A82] [85]
Obinutuzumab DM3BVAE Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Obinutuzumab. Mature B-cell leukaemia [2A82] [85]
Idelalisib DM602WT Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Idelalisib. Mature B-cell leukaemia [2A82] [85]
GDC-0199 DMH0QKA Moderate Additive myelosuppressive effects by the combination of Ganciclovir and GDC-0199. Mature B-cell leukaemia [2A82] [85]
IPI-145 DMWA24P Moderate Additive myelosuppressive effects by the combination of Ganciclovir and IPI-145. Mature B-cell leukaemia [2A82] [85]
Acalabrutinib DM7GCVW Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Acalabrutinib. Mature B-cell lymphoma [2A85] [85]
Blinatumomab DMGECIJ Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Blinatumomab. Mature B-cell lymphoma [2A85] [85]
Ibrutinib DMHZCPO Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Ibrutinib. Mature B-cell lymphoma [2A85] [85]
Tisagenlecleucel DMM9BJD Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Tisagenlecleucel. Mature B-cell lymphoma [2A85] [85]
Mercaptopurine DMTM2IK Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Mercaptopurine. Mature B-cell lymphoma [2A85] [85]
Exjade DMHPRWG Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Exjade. Mineral absorption/transport disorder [5C64] [85]
Carfilzomib DM48K0X Moderate Increased risk of nephrotoxicity by the combination of Ganciclovir and Carfilzomib. Multiple myeloma [2A83] [85]
Panobinostat DM58WKG Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Panobinostat. Multiple myeloma [2A83] [85]
Thalidomide DM70BU5 Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Thalidomide. Multiple myeloma [2A83] [85]
Selinexor DMBD4K3 Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Selinexor. Multiple myeloma [2A83] [85]
Belantamab mafodotin DMBT3AI Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Belantamab mafodotin. Multiple myeloma [2A83] [85]
Elotuzumab DMEYHG9 Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Elotuzumab. Multiple myeloma [2A83] [85]
Daratumumab DMKCIUZ Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Daratumumab. Multiple myeloma [2A83] [85]
Melphalan DMOLNHF Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Melphalan. Multiple myeloma [2A83] [85]
Romidepsin DMT5GNL Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Romidepsin. Mycosis fungoides [2B01] [85]
Decitabine DMQL8XJ Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Decitabine. Myelodysplastic syndrome [2A37] [85]
Nilotinib DM7HXWT Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Nilotinib. Myeloproliferative neoplasm [2A20] [85]
Ruxolitinib DM7Q98D Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Ruxolitinib. Myeloproliferative neoplasm [2A20] [85]
Dasatinib DMJV2EK Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Dasatinib. Myeloproliferative neoplasm [2A20] [85]
Hydroxyurea DMOQVU9 Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Hydroxyurea. Myeloproliferative neoplasm [2A20] [85]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [85]
Busulfan DMXYJ9C Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Busulfan. Myeloproliferative neoplasm [2A20] [85]
Olaparib DM8QB1D Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Olaparib. Ovarian cancer [2C73] [85]
Rucaparib DM9PVX8 Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Rucaparib. Ovarian cancer [2C73] [85]
MK-4827 DMLYGH4 Moderate Additive myelosuppressive effects by the combination of Ganciclovir and MK-4827. Ovarian cancer [2C73] [85]
Topotecan DMP6G8T Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Topotecan. Ovarian cancer [2C73] [85]
Upadacitinib DM32B5U Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Upadacitinib. Rheumatoid arthritis [FA20] [85]
Baricitinib DM4ONW5 Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Baricitinib. Rheumatoid arthritis [FA20] [85]
Tofacitinib DMBS370 Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Tofacitinib. Rheumatoid arthritis [FA20] [85]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Ganciclovir and Golimumab. Rheumatoid arthritis [FA20] [88]
Sarilumab DMOGNXY Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Sarilumab. Rheumatoid arthritis [FA20] [85]
Leflunomide DMR8ONJ Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Leflunomide. Rheumatoid arthritis [FA20] [85]
Mogamulizumab DMISH0Z Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Mogamulizumab. Sezary syndrome [2B02] [85]
PDX-101 DM6OC53 Moderate Additive myelosuppressive effects by the combination of Ganciclovir and PDX-101. Solid tumour/cancer [2A00-2F9Z] [85]
Ifosfamide DMCT3I8 Moderate Increased risk of nephrotoxicity by the combination of Ganciclovir and Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [85]
Docetaxel DMDI269 Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Docetaxel. Solid tumour/cancer [2A00-2F9Z] [85]
Trabectedin DMG3Y89 Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [85]
Mitoxantrone DMM39BF Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Mitoxantrone. Solid tumour/cancer [2A00-2F9Z] [85]
LEE011 DMMX75K Moderate Additive myelosuppressive effects by the combination of Ganciclovir and LEE011. Solid tumour/cancer [2A00-2F9Z] [85]
Taxol DMUOT9V Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Taxol. Solid tumour/cancer [2A00-2F9Z] [85]
Pomalidomide DMTGBAX Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Pomalidomide. Systemic sclerosis [4A42] [85]
Plicamycin DM7C8YV Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Plicamycin. Testicular cancer [2C80] [85]
Trimetrexate DMDEA85 Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Trimetrexate. Toxoplasmosis [1F57] [85]
Procainamide DMNMXR8 Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Procainamide. Ventricular tachyarrhythmia [BC71] [85]
Tocainide DMYNMDP Moderate Additive myelosuppressive effects by the combination of Ganciclovir and Tocainide. Ventricular tachyarrhythmia [BC71] [85]
⏷ Show the Full List of 85 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 2 E00446 2723854 Colorant
Hydrochloric acid E00015 313 Acidulant
Carmellose sodium E00625 Not Available Disintegrant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Sodium hydroxide E00234 14798 Alkalizing agent
Soybean lecithin E00637 Not Available Other agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Ganciclovir 250 mg capsule 250 mg Oral Capsule Oral
Ganciclovir 500 mg capsule 500 mg Oral Capsule Oral
Ganciclovir Sodium eq 500mg base/vial injectable eq 500mg base/vial Injectable Injection
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
7 Application of real time polymerase chain reaction to the diagnosis and treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Zhonghua Xue Ye Xue Za Zhi. 2009 Feb;30(2):77-81.
8 Amino Acid Transporter ATB0,+ as a delivery system for drugs and prodrugs. Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec;5(4):357-64.
9 Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5). Drug Metab Rev. 2005;37(1):253-78.
10 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
11 Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
12 Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
13 Side populations of glioblastoma cells are less sensitive to HSV-TK/GCV suicide gene therapy system than the non-side population. In Vitro Cell Dev Biol Anim. 2010 Jun;46(6):497-501.
14 FDA Drug Development and Drug Interactions
15 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
16 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
17 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
18 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
19 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
20 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
21 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
22 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
23 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
24 Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010 Apr;298(4):F997-F1005.
25 Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother. 2011 Jul;55(7):3091-8.
26 Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. J Pharmacol Exp Ther. 2010 Aug;334(2):651-6.
27 Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 2019 May;105(5):1187-1195.
28 Expression of Organic Anion Transporter 1 or 3 in Human Kidney Proximal Tubule Cells Reduces Cisplatin Sensitivity. Drug Metab Dispos. 2018 May;46(5):592-599.
29 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
30 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
31 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
32 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
33 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
34 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
35 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
36 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
37 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
38 Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007 Jan;320(1):229-35.
39 Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50.
40 ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
41 The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9.
42 Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361-7.
43 P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice. Drug Metab Lett. 2010 Dec;4(4):195-201.
44 Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood. 2009 Aug 13;114(7):1383-6.
45 Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochem J. 2002 Feb 1;361(Pt 3):497-503.
46 Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
47 The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res. 2005 May 15;65(10):4425-30.
48 Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy. Curr Cancer Drug Targets. 2008 Aug;8(5):414-20.
49 Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine. Springerplus. 2014 Dec 13;3:732.
50 Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia. 2010 Sep;12(9):740-7.
51 Hyaluronan export by the ABC transporter MRP5 and its modulation by intracellular cGMP. J Biol Chem. 2007 Jul 20;282(29):20999-1004.
52 Kinetic validation of the use of carboxydichlorofluorescein as a drug surrogate for MRP5-mediated transport. Eur J Pharm Sci. 2006 Apr;27(5):524-32.
53 Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci. 2002;4(3):E14.
54 The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem. 2000 Sep 29;275(39):30069-74.
55 The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos. 2002 Jan;30(1):13-9.
56 Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: Comparison with methotrexate. Drug Metab Pharmacokinet. 2010;25(2):163-9.
57 Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
58 Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res. 2004 Jan;21(1):61-7.
59 Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
60 Interaction of zalcitabine with human organic anion transporter 1. Pharmazie. 2006 May;61(5):491-2.
61 Apical expression or expression in a non polarized cell of hOAT1 inverses regulation by epidermal growth factor (EGF) as compared to basolateral hOAT1. Cell Physiol Biochem. 2004;14(3):177-86.
62 Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):641-8.
63 Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet. 2004 Oct;19(5):369-74.
64 Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86.
65 Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8.
66 Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. Am J Physiol Cell Physiol. 2005 Nov;289(5):C1075-84.
67 Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J Neurochem. 2004 Aug;90(4):931-41.
68 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
69 The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther. 2007 Sep;322(3):1221-7.
70 Aspirin and probenecid inhibit organic anion transporter 3-mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat. Drug Metab Dispos. 2014 Jun;42(6):996-1007.
71 A polarized localization of amino acid/carnitine transporter B(0,+) (ATB(0,+)) in the blood-brain barrier. Biochem Biophys Res Commun. 2008 Nov 14;376(2):267-70.
72 Transport of butyryl-L-carnitine, a potential prodrug, via the carnitine transporter OCTN2 and the amino acid transporter ATB(0,+). Am J Physiol Gastrointest Liver Physiol. 2007 Nov;293(5):G1046-53.
73 High-affinity glutamate transporter GLAST/EAAT1 regulates cell surface expression of glutamine/neutral amino acid transporter ASCT2 in human fetal astrocytes. Neurochem Int. 2006 May-Jun;48(6-7):611-5.
74 Transport of amino acid-based prodrugs by the Na+- and Cl(-) -coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery. J Pharmacol Exp Ther. 2004 Mar;308(3):1138-47.
75 Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0,+). Pharm Res. 2004 Jul;21(7):1303-10.
76 Functional regulation of Na+-dependent neutral amino acid transporter ASCT2 by S-nitrosothiols and nitric oxide in Caco-2 cells. FEBS Lett. 2005 Apr 25;579(11):2499-506.
77 D-Serine Is a Substrate for Neutral Amino Acid Transporters ASCT1/SLC1A4 and ASCT2/SLC1A5, and Is Transported by Both Subtypes in Rat Hippocampal Astrocyte Cultures. PLoS One. 2016 Jun 7;11(6):e0156551.
78 Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther. 2009 Apr;8(4):864-72.
79 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
80 Extensive oral shedding of human herpesvirus 8 in a renal allograft recipient. Oral Microbiol Immunol. 2009 Apr;24(2):109-15.
81 Drug targets in cytomegalovirus infection. Infect Disord Drug Targets. 2009 Apr;9(2):201-22.
82 Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides. Drugs. 2009;69(2):151-66.
83 Penciclovir cream--improved topical treatment for herpes simplex infections. Skin Pharmacol Physiol. 2004 Sep-Oct;17(5):214-8.
84 Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment. Drugs. 1999 Feb;57(2):187-206.
85 Cerner Multum, Inc. "Australian Product Information.".
86 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
87 Product Information. Cytovene (ganciclovir). Genentech, South San Francisco, CA.
88 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.